Equillium (NASDAQ:EQ) Now Covered by Analysts at Leerink Partners

Leerink Partners started coverage on shares of Equillium (NASDAQ:EQ) in a research note issued to investors on Monday, MarketBeat.com reports. The brokerage issued an outperform rating and a $6.00 target price on the stock.

Several other research firms have also weighed in on EQ. Wall Street Zen lowered Equillium from a “hold” rating to a “sell” rating in a research report on Saturday, September 19th. Clear Str upgraded Equillium to a “strong-buy” rating in a research report on Tuesday, July 21st. Weiss Ratings restated a “sell (d-)” rating on shares of Equillium in a research report on Monday, September 21st. Roth Capital reaffirmed a “buy” rating and set a $12.00 target price on shares of Equillium in a research note on Friday, September 4th. Finally, Zacks Research raised Equillium from a “strong sell” rating to a “hold” rating in a research note on Tuesday, August 11th. Two research analysts have rated the stock with a Strong Buy rating, seven have given a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $7.57.

Equillium Trading Up 6.4%

Shares of Equillium stock opened at $1.50 on Monday. The company’s 50-day moving average price is $2.02 and its two-hundred day moving average price is $2.30. Equillium has a 52 week low of $0.76 and a 52 week high of $3.54. The stock has a market cap of $95.11 million, a PE ratio of -7.50 and a beta of 1.93.

Equillium (NASDAQ:EQ) last posted its quarterly earnings results on Thursday, August 13th. The company reported ($0.04) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.05) by $0.01. On average, equities analysts predict that Equillium will post -0.21 EPS for the current fiscal year.

Institutional Trading of Equillium

Large investors have recently made changes to their positions in the stock. Two Sigma Securities LLC bought a new position in shares of Equillium in the 2nd quarter valued at approximately $35,000. Coastal Bridge Advisors LLC acquired a new stake in Equillium in the 2nd quarter worth approximately $48,000. Dimensional Fund Advisors LP bought a new stake in Equillium during the first quarter worth approximately $31,000. High Net Worth Advisory Group LLC bought a new stake in Equillium during the second quarter worth approximately $107,000. Finally, Jefferies Financial Group Inc. bought a new stake in Equillium during the second quarter worth approximately $109,000. Institutional investors own 27.05% of the company’s stock.

Equillium Company Profile

Equillium, Inc is a clinical-stage biotechnology company focused on developing therapies for severe autoimmune and inflammatory diseases. The company’s approach centers on modulating immune pathways involved in disease progression, with the goal of addressing conditions that have limited treatment options.

Equillium’s lead product candidate is itolizumab, a monoclonal antibody that targets CD6, an immune-cell receptor involved in the regulation of T-cell activity. The company is evaluating itolizumab in immune-mediated conditions, including acute graft-versus-host disease and lupus nephritis.